Lexicon Pharmaceuticals, Inc. (LXRX) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$1.60
Price Target
$6.00
Target Range
$6.00 — $6.00
Analyst Rating
Hold
Forward P/E—
Trailing P/E-11.4x
Forward PEG—
Implied Growth-27.9%
Median Target$6.00
Analyst Spread0.0%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$6
+275.0%
Consensus
$6
+275.0%
Bull Case
$6
+275.0%
LXRX Price Target Analysis
Updated May 7, 2026As of May 7, 2026, Lexicon Pharmaceuticals, Inc. (LXRX) has a Wall Street consensus price target of $6.00, based on estimates from 14 covering analysts. With the stock currently trading at $1.60, this represents a potential upside of +275.0%. The company has a market capitalization of $678M.
Analyst price targets range from a low of $6.00 to a high of $6.00, representing a 0% spread in expectations. The median target of $6.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Hold, with 5 analysts rating the stock as a Buy or Strong Buy,7 rating it Hold, and 2 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, LXRX trades at a trailing P/E of -11.4x. Analysts expect EPS to grow -27.9% over the next year.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+49.4%
Avg Forward P/E49.6x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 ARDXArdelyx, Inc. | $1.7B | $7.10 | $17.00 | +139.4% | Buy | — | 16 |
 CORTCorcept Therapeutics Incorporated | $5.6B | $52.15 | $71.67 | +37.4% | Buy | 138.9x | 25 |
 INVAInnoviva, Inc. | $1.9B | $22.52 | $37.67 | +67.3% | Buy | 11.8x | 10 |
 PTGXProtagonist Therapeutics, Inc. | $6.6B | $103.97 | $116.75 | +12.3% | Buy | 32.2x | 26 |
 ACADACADIA Pharmaceuticals Inc. | $3.7B | $21.48 | $34.78 | +61.9% | Buy | 48.5x | 37 |
 AGIOAgios Pharmaceuticals, Inc. | $1.6B | $26.98 | $37.75 | +39.9% | Buy | — | 29 |
 FOLDAmicus Therapeutics, Inc. | $4.5B | $14.49 | $14.50 | +0.1% | Buy | 40.6x | 24 |
 RAREUltragenyx Pharmaceutical Inc. | $2.5B | $25.93 | $51.50 | +98.6% | Buy | — | 33 |
 MDGLMadrigal Pharmaceuticals, Inc. | $12.4B | $539.73 | $705.67 | +30.7% | Buy | — | 23 |
 ELANElanco Animal Health Incorporated | $13.1B | $26.16 | $27.88 | +6.6% | Buy | 25.4x | 20 |
Upside Potential Comparison
ARDXRAREINVAACADAGIOCORTMDGLPTGXSee LXRX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs LXRX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare LXRX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonLXRX — Frequently Asked Questions
Quick answers to the most common questions about buying LXRX stock.
What is the LXRX stock price target for 2026?
The consensus Wall Street price target for LXRX is $6, representing 275.0% upside from the current price of $1.6. With 14 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
Is LXRX a buy, sell, or hold?
LXRX has a consensus rating of "Hold" based on 14 Wall Street analysts. The rating breakdown is mixed, with 7 Hold ratings making up the largest segment. The consensus 12-month price target of $6 implies 275.0% upside from current levels.
Is LXRX stock overvalued or undervalued?
LXRX's current price is $1.6 with a consensus target of $6 (275.0% implied move). Analyst estimates suggest the stock is undervalued at current levels.
How high can LXRX stock go?
The most bullish Wall Street analyst has a price target of $6 for LXRX, while the most conservative target is $6. The consensus of $6 represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover LXRX stock?
LXRX is moderately covered, with 14 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 5 have Buy ratings, 7 recommend Hold, and 2 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the LXRX stock forecast?
The 12-month LXRX stock forecast based on 14 Wall Street analysts shows a consensus price target of $6, with estimates ranging from $6 (bear case) to $6 (bull case). The median consensus rating is "Hold".
Should I buy LXRX stock?
Wall Street analysts are very optimistic on LXRX, with a "Hold" consensus rating and $6 price target (275.0% upside). 5 of 14 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do LXRX price targets vary so much?
LXRX analyst price targets range from $6 to $6, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $6 consensus represents the middle ground.